Benzinga's Microcap Movers for Monday January 30, 2012

Below are highlights from Benzinga's daily coverage of microcap securities making big moves:

Shares of NeurogesX

, the San Mateo, CA biopharmaceutical company, rose 17% Monday on 9 times the average daily volume. A spokesperson for NeurogesX said there was no news releases today to account for the move. The company is awaiting an FDA panel scheduled for February 9 for review of Qutenza, a treatment for HIV Associated Peripheral Neuropathy. NeurogesX closed at $1.07 Monday.

Shares of Medisafe 1 Technologies (

), the Israel-based developer of patented technologies that physically prevent unauthorized administration of prescription medications, rose 86% Monday on 110 times the average daily volume. Medisafe announced Monday that the company's Board of Directors has approved a stock repurchase program. Under the program, Medisafe 1 Technologies is authorized to repurchase up to 10 million of its outstanding shares of common stock during the next 12 months at a price up to $0.10 per share on the open market or by conducting privately negotiated transactions depending on current market conditions and other factors. Medisafe 1 Technologies closed at $0.03 Monday.

Shares of Vringo

, the New York, NY mobile video application developer, rose 14.85% Monday on 22 times the average daily volume. Vringo develops apps for the Facebook platform and the announcement of the Facebook IPO filing, contributed to a 70% price rise since last Wednesday. Vringo closed at $1.16 Monday.